Stakeholders weigh in on BsUFA IV enhancements
Regulatory NewsJoanne S. Eglovitch
Biologics License Application (BLA)Biologics/ biosimilars/ vaccinesBsUFAProduct developmentRegulatory Intelligence/PolicyRegulatory strategyUnited StatesUS Food and Drug Administration (FDA)